The UK digital diabetes management market is poised for significant growth, with analysts predicting a 22% compound annual growth rate (CAGR) until 2028. This rapid expansion is driven by technological advancements, innovative solutions, and a growing focus on personalised care.
According to Technavio, the market is set to reach an estimated £15 billion by 2028, reflecting a substantial rise from its current value. This growth is attributed to factors such as the increasing adoption of wearable devices, cloud-based solutions, and the integration of artificial intelligence (AI).
The report highlights several key drivers behind this market boom:
Wearable technology: Manufacturers are continuously developing more compact, lightweight, and user-friendly wearable medical devices, incorporating advanced technologies such as system-on-chip (SoC) and chip-scale package (CSP). This development allows for more accessible and convenient glucose monitoring and insulin delivery.
Cloud-based solutions: Cloud-based enterprise solutions are enabling seamless data sharing and remote patient monitoring. This shift towards telehealth solutions is reducing the need for frequent clinic visits, empowering patients to manage their diabetes more effectively.
Artificial intelligence (AI): AI-powered algorithms analyse data from wearables, smart insulin meters, and other devices to provide continuous glucose monitoring and optimise insulin delivery. This data-driven approach enhances the precision of treatment plans and promotes better diabetes management.
Big data analytics: Data management software and big data analytics provide healthcare professionals with comprehensive insights into patient data, enabling them to make more informed decisions and tailor treatment plans to individual needs.
This surge in digital diabetes management solutions reflects a wider trend towards personalised healthcare, where individuals are actively engaged in their treatment and empowered to take control of their health. The market is expected to see further development of innovative technologies, including advanced AI applications and remote patient monitoring platforms, further enhancing the effectiveness of diabetes management in the coming years.